The Investor Newsletter Daily

Prosper Junior Bakiny, The Motley Fool January 11, 2026 at 4:05 PM Key Points Structure Therapeutics’ positive phase 2 data for aleniglipron sent its

Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be

Avi Kapoor January 7, 2026 at 9:00 AM As of Jan. 6, 2026, two stocks in the information technology sector could be flashing a

These stocks are poised for substantial growth. The “Magnificent Seven” are among the most profitable and cash-rich businesses on the planet. These companies are

Macro conditions have not delivered a clear catalyst. Some composite financial-condition gauges sit slightly supportive, but they remain close to neutral. In addition, search

The stock market is at highs with JPMorgan, Goldman, Taiwan Semi and Delta earnings due. Two huge conferences, inflation data and perhaps a Trump

Baird analyst Ben Kallo cut his rating on the stock to Hold from Buy. He slashed his price target by $167 to $649 a

AGNC Investment’s dividend yield is more than twice that of Realty Income’s, but does that make it the better dividend stock?

Viewers of a TikTok clip about cryptocurrency are locked in a heated debate after a famous economist claimed no one is using crypto for

The five biggest winners of 2025 were Bitcoin Cash (CRYPTO: BCH), Zcash (CRYPTO: ZEC), Monero (CRYPTO: XMR), Pax Gold (CRYPTO: PAXG), and MYX Finance